Table 1.
Patient Characteristics
| Normal Proliferative1 N=18 N(%) | Normal Secretory1 N=10 N(%) | Simple1 N=23 N(%) | Hyperplasia Complex2 N=83 N(%) | Atypia2 N=54 N(%) | Carcinoma1 N=15 N(%) | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| ≤39 | 4 (22.2) | 4 (40.0) | 2 (8.7) | 8 (9.6) | 4 (7.4) | 1 (6.7) |
| 40-49 | 10 (55.6) | 5 (50.0) | 8 (34.8) | 22 (26.5) | 9 (16.7) | 0 (0.0) |
| 50-59 | 3 (16.7) | 1 (10.0) | 11 (47.8) | 22 (26.5) | 21 (38.9) | 7 (46.7) |
| 60-69 | 0 (0.0) | 0 (0.0) | 2 (8.7) | 21 (25.3) | 8 (14.8) | 4 (26.7) |
| ≥70 | 1 (5.6) | 0 (0.0) | 0 (0.0) | 10 (12.1) | 12 (22.2) | 3 (20.0) |
| Diabetes3 | 0 (0.0) | 0 (0.0) | 1 (4.4) | 7 (9.0) | 5 (10.0) | 4 (26.7) |
| Breast/Colon Cancer3 | 1 (5.6) | 0 (0.0) | 2 (8.7) | 2 (2.6) | 4 (8.0) | 0 (0.0) |
| Current Smoker3 | 1 (5.6) | 3 (30.0) | 1 (5.0) | 8 (11.0) | 4 (8.0) | 2 (13.3) |
| BMI (kg/m2)3 | ||||||
| <25 | 3 (21.4) | 3 (37.5) | 2 (9.5) | 20 (25.6) | 13 (26.5) | 1 (6.7) |
| 25-29.9 | 4 (28.6) | 2 (25.0) | 6 (28.6) | 18 (23.1) | 13 (26.5) | 3 (20.0) |
| ≥30 | 7 (50.0) | 3 (37.5) | 13 (61.9) | 40 (51.3) | 23 (46.9) | 11 (73.3) |
| Nulliparous3 | 6 (35.3) | 3 (30.0) | 10 (47.6) | 14 (18.2) | 15 (30.0) | 3 (20.0) |
| Oral contraceptive4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (3.6) | 0 (0.0) | 0 (0.0) |
| HT4,5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (10.8) | 5 (9.3) | 2 (13.3) |
| Unopposed Estrogen4,6 | 0 (0.0) | 0 (0.0) | 1 (4.4) | 12 (14.5) | 3 (5.6) | 0 (0.0) |
| Progestin only4,7 | 0 (0.0) | 0 (0.0) | 2 (8.7) | 2 (2.4) | 1 (1.9) | 1 (6.7) |
| Index biopsy year | ||||||
| 1985-1989 | 4 (4.8) | 0 (0.0) | ||||
| 1990-1994 | 21 (25.3) | 13 (24.1) | ||||
| 1995-1999 | 24 (28.9) | 28 (51.9) | ||||
| 2000-2004 | 34 (41.0) | 13 (24.1) | ||||
| 2005-2009 | 18 (100.0) | 10 (100.0) | 23 (100.0) | 0 (0.0) | 0 (0.0) | 15 (100.0) |
Abbreviations: BMI=body mass index in kg per meters squared, HT = postmenopausal estrogen and progestin therapy
University of Washington Medical Center (UWMC) specimens
Endometrial Cohort (ECO) Study specimens
For ECO cohort, missing data on: diabetes - 9; history of breast/colon cancer, BMI, parity - 10; smoking - 14. For UWMC cohort, missing data on; smoke and parity - 3; BMI – 8, only weight available for 17 UWMC women, weight ≥198 categorized as BMI >30 kg/m2 (4 women), weight ≤128 categorized as <25 kg/m2 (6 women) and weight between 128 and 198 pounds categorized as BMI missing (7 women)
Dispensed in the six months preceding diagnosis of endometrial hyperplasia.
HT (estrogen plus progestin for 2 months or more and the progestin was dispensed for at least 1/3 of the time that estrogen was dispensed)
Unopposed estrogen = postmenopausal estrogen therapy (estrogen alone or estrogen plus progestin for 2 months or more and the progestin was dispensed less than 1/3 of the time that estrogen was dispensed)
Dispensed for at least 2 months.